|Mr. Arthur S. Przybyl||Pres, CEO & Director||1.43M||2.46M||1957|
|Mr. Stephen P. Carey||CFO & VP of Fin.||680.93k||N/A||1971|
|Mr. James G. Marken||Sr. VP of Operations & Product Devel.||592.16k||1.13M||1963|
|Mr. Robert W. Schrepfer||Sr. VP of Bus. Devel. & Specialty Sales||686.33k||2.74M||1972|
ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract manufacturing for other pharmaceutical companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was founded in 2001 and is headquartered in Baudette, Minnesota.
ANI Pharmaceuticals, Inc.’s ISS Governance QualityScore as of April 1, 2019 is 4. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 1; Compensation: 8.